Foundayo vs Wegovy vs Zepbound: Cost, Coverage & Which to Fight For

You've heard the buzz about a GLP-1 pill — no injections, once-a-day, and suddenly there are three serious options on the pharmacy shelf at the same time.

The problem is that knowing which drug exists is only half the battle. The real question is which one you can actually afford and get covered — and those answers are very different depending on your insurance situation.

We dug into every verified cost and coverage path so you don't have to.

Specifically, you'll learn: how Foundayo, Wegovy, and Zepbound stack up on price and form, what each one costs with and without insurance in 2026, which coverage angles are strongest for each drug, and exactly where to focus your energy when a plan says no.

The Three Drugs at a Glance

Before we get into dollars, here is a plain-English snapshot of what you are actually comparing.

Wegovy is injectable semaglutide — a once-weekly pen shot that has been on the market long enough to have a substantial insurance track record. It is FDA-approved for chronic weight management in adults with obesity, or overweight with a weight-related condition. It also carries an FDA approval to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight — a coverage angle we will come back to.

Zepbound is injectable tirzepatide from Eli Lilly, also once-weekly, also approved for weight management. Because tirzepatide works on two hormone receptors instead of one, Zepbound showed stronger average weight-loss results in clinical trials than earlier semaglutide data — though individual results always vary and your clinician is the right person to interpret that for your situation.

Foundayo is the newcomer. It is the brand name for orforglipron, the first oral GLP-1 pill approved by the FDA for weight loss — cleared on April 1, 2026. You take it once a day, no injection required. That matters a lot for people with needle anxiety or who simply want a pill. Its list self-pay price starts at $149 per month, which is meaningfully lower than either injectable option at list price.

One more thing to flag before we go further: never purchase "semaglutide" or any GLP-1 from unverified online sellers or gray-market "research peptide" sources. Counterfeits are widespread, have caused hospitalizations, and may contain the wrong dose or the wrong substance entirely. Stick to licensed pharmacies and verified manufacturer programs.

All figures are as of June 2026 and subject to change — verify current prices directly with the manufacturer or pharmacy before making any decision.

Real-World Cost: What You Actually Pay

List prices are almost fiction. What matters is the lowest verified path to getting the drug in your hands each month.

Here is how the three drugs compare on actual out-of-pocket cost right now (as of June 2026).

Here's the deal:

The cheapest commercial cash-pay option is Foundayo at $149 per month for the lowest dose — and it can drop as low as $25 per month if you have qualifying commercial insurance and use the manufacturer savings card.

Wegovy has a time-limited introductory offer: $199 per month for the first two fills for new patients (through June 30, 2026), then approximately $349 per month for most doses (or $399 for the higher-dose HD version) through the Wegovy Savings Offer. That is a real program with real teeth — but the introductory window closes.

Zepbound self-pay vials through LillyDirect start at approximately $299 per month for lower doses, with higher doses costing more. Lilly's direct-dispensing model bypasses the traditional pharmacy channel, which is part of why the price is lower than list.

The savings card trap you need to know about

Manufacturer savings cards — including Foundayo's $25 option and Wegovy's savings program — almost always require commercial (employer or individual marketplace) insurance.

They explicitly exclude Medicare, Medicaid, Tricare, and other federal programs.

That is the number-one reason people show up at the pharmacy expecting $25 and walk away paying full price. If you are on a government plan, the savings card simply does not apply — and you need a different strategy entirely (more on that in the Medicare and Medicaid section below).

For a full side-by-side breakdown of every legitimate way to lower GLP-1 costs — including programs for people without insurance — see our GLP-1 cost ladder.

Insurance Coverage: Why the Same Drug Plays Differently

Here is the single most important thing to understand about GLP-1 coverage: your diagnosis matters as much as the drug itself.

Coverage for GLP-1s for type 2 diabetes is near-universal across commercial plans, Medicare, and Medicaid. Coverage for weight loss is the variable — it depends entirely on your specific plan's benefit design, and many plans simply exclude anti-obesity medications as a category.

Let that sink in:

The same molecule — semaglutide — can be covered under Ozempic (diabetes approval) but denied under Wegovy (weight-loss approval), on the very same insurance plan, for the very same patient, because the approved indication is different.

What prior authorization actually requires

For plans that do cover weight-loss GLP-1s, prior authorization is almost always required. Here is what they check:

• BMI at or above 30 (obesity), OR BMI at or above 27 (overweight) with at least one qualifying condition — hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
• Documented participation in a reduced-calorie diet and increased physical activity — often for a specific period (commonly 3 to 6 months)
• Step therapy completion — some plans require you to have tried and failed a preferred or cheaper drug first
• An FDA-approved indication that matches the request (requesting a weight-loss drug for weight loss; a diabetes-only drug for weight loss will be denied)
• Prescriber attestation and supporting chart documentation for every criterion above

The most common denial reasons are not that you don't qualify — they are that the documentation is incomplete or the framing is wrong.

The cardiovascular angle that most people miss

Wegovy has a coverage lever the other two drugs do not: an FDA approval to reduce cardiovascular risk in adults with established cardiovascular disease who also have obesity or overweight.

For patients with a documented cardiovascular history, framing the Wegovy request around that indication — rather than pure weight loss — can clear a denial that would otherwise stick. Many plans that carve out weight-loss medications still cover cardiovascular risk-reduction drugs.

This is not a workaround or a loophole. It is the correct medical framing for the correct patient. Your prescriber needs to document the cardiovascular history and align the request to that indication.

Neither Zepbound nor Foundayo currently holds that cardiovascular indication — which is a meaningful coverage distinction in 2026.

For a step-by-step guide on navigating insurance for Zepbound specifically, see How to Get Zepbound Covered by Insurance in 2026.

The appeal ladder when you get denied

A denial is not the end. Here is how to climb it:

• Internal appeal #1: Submit a letter of medical necessity that ties your documented record to each named prior-auth criterion, point by point
• Peer-to-peer review: Your prescriber speaks directly with the plan's medical director — this step alone reverses a substantial number of denials
• Internal appeal #2: Add any newly available documentation (updated BMI, lab work, specialist notes)
• External review: An independent review organization looks at the case — this is often where benefit-exclusion vs. medical-necessity gets properly tested

One honest caveat: if your plan has a hard benefit exclusion — meaning it does not cover weight-loss drugs at all as a category — appeals rarely change that outcome. At that point, the smartest move is to pivot to a covered indication (cardiovascular for Wegovy, diabetes if applicable), the Medicare Bridge if you qualify, or a verified cash-pay path.

You can walk through the full appeal process on our appeal guide.

Medicare and Medicaid: The 2026 Landscape

If you are on a government health plan, the rules are different — and in 2026, they are changing fast.

Medicare: The GLP-1 Bridge is real, but limited

Standard Medicare still does not cover GLP-1 medications for weight loss outside of specific approved uses like diabetes or cardiovascular disease.

But starting July 1, 2026, a new Medicare GLP-1 Bridge demonstration program creates the first real weight-loss coverage path for some Part D members.

Under the Bridge, eligible members pay approximately $50 per month after the deductible for covered drugs. The covered drugs include injectable Wegovy, Zepbound, Mounjaro, and Ozempic — plus the Wegovy pill and Foundayo (orforglipron).

Here's the catch:

The Bridge is a limited, time-bound demonstration program — not permanent coverage. Not every Part D plan participates, and not every person qualifies. If you are on Medicare and interested, you need to verify with your specific plan whether it is enrolled in the Bridge before July 1.

The $50 per month cost makes Foundayo especially interesting for Medicare patients who qualify — it would be the first time many of them could access a GLP-1 for weight loss at a manageable monthly cost.

Medicaid: A state-by-state patchwork

Medicaid coverage for GLP-1 weight-loss drugs varies enormously by state. As of mid-2026, 13 states have confirmed coverage. Three states — California, Michigan, and Pennsylvania — have confirmed they are cutting weight-loss GLP-1 coverage in 2026.

Medicaid coverage for GLP-1s used for type 2 diabetes is available in nearly every state, which again brings the diabetes-indication framing back into play for eligible patients.

Check your state's current status on our Medicaid GLP-1 coverage tracker.

Which One Should You Fight to Get Covered?

This is the practical question. Here is how to think about it based on your situation.

Bottom line up front:

If you have commercial insurance and an established cardiovascular history: Fight for Wegovy first. The cardiovascular indication is a coverage lever that neither Zepbound nor Foundayo can match right now. Frame the prior auth request around cardiovascular risk reduction, not weight loss.

If you have commercial insurance and no cardiovascular history: Wegovy and Zepbound are roughly equal on coverage fight-ability — both are approved for weight loss, both have strong formulary presence. Zepbound's self-pay vial program gives it a better cash-pay fallback if coverage fails. For the easiest potential path to getting started cheaply while coverage is pending, Foundayo's $149 self-pay or $25 savings-card price means lower stakes while you wait for a PA decision.

If you have type 2 diabetes: Ozempic (semaglutide) or Mounjaro (tirzepatide) are approved for diabetes and covered far more readily for that indication. Talk to your clinician about whether a diabetes-approved drug is appropriate for your situation — the coverage friction is dramatically lower.

If you are on Medicare: Starting July 1, 2026, the GLP-1 Bridge makes Foundayo the most financially accessible option at roughly $50 per month for qualifying Part D members — but verify your plan is enrolled.

If you hate injections: Foundayo and the Wegovy pill are your two oral options. Foundayo's lower list self-pay price ($149 vs. approximately $149–$199 for the Wegovy pill depending on dose and timing) gives it a slight edge on out-of-pocket cost, but both are genuinely comparable.

All prices as of June 2026 — verify before you fill.

When Insurance Won't Budge: Your Cash-Pay Backup

Sometimes the appeals are exhausted. Sometimes the plan has a hard exclusion that no letter will move. Here is where to go next.

Foundayo (orforglipron) is the most affordable verified entry point in 2026 at $149 per month self-pay for the lowest dose. If you have commercial insurance and qualify for the savings card, $25 per month is the floor. There are dose limits and the program terms can change, so confirm details directly with the manufacturer.

Zepbound self-pay vials through LillyDirect start at approximately $299 per month for lower doses. This is a legitimate, direct-from-manufacturer path that many patients use while their insurance coverage is pending or appealed. Higher doses cost more — the exact price depends on which dose your clinician prescribes.

Wegovy Savings Offer brings the cost to $199 per month for the first two fills (new patients, through June 30, 2026), then approximately $349 per month afterward. That is still real money, but it is a verified path for patients on commercial insurance who cannot get coverage to move.

One thing we want to be clear about:

None of the cash-pay programs above require insurance — but they do have eligibility rules, dose limits, and expiration dates that can change. Always verify current terms directly. And again: never buy GLP-1 drugs from unverified online sellers. The counterfeit market is dangerous.

For context on what happened with compounded semaglutide and what legitimate cheaper options replaced it, see Compounded Semaglutide Is Ending — Your Safe, Cheaper Options.

If your situation involves no insurance at all and you are primarily interested in semaglutide, our detailed guide on The Cheapest Legitimate Way to Get Ozempic Without Insurance (2026) walks through every verified option.

Your Next Move

Foundayo is genuinely new and genuinely cheaper on paper — but which drug you should pursue depends almost entirely on your insurance situation, your medical history, and which coverage angle is strongest for your specific case.

If you have a cardiovascular history, Wegovy's CV indication is still the most powerful single coverage lever available in 2026. If you are on Medicare and the Bridge applies to you, Foundayo at roughly $50 per month is a meaningful breakthrough. If you are paying cash and want the lowest monthly cost, Foundayo at $149 (or $25 with a commercial savings card) leads the field right now.

Which situation fits yours most closely — and which drug are you trying to get covered?